Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has reported that the FDA has granted final approval for the company's abbreviated new drug application to market its generic version of Dey's bronchodilator, DuoNeb inhalation solution, 3mg and 0.5mg.
Subscribe to our email newsletter
The drug is indicated to treat breathing difficulty in patients with chronic obstructive pulmonary disease (COPD). Shipment of the product will begin immediately.
The company claims that the brand product had annual sales of approximately $265 million in the US for the twelve months ended September 30, 2007, based on IMS sales data.